Giuseppe Banna: A Comprehensive and Updated Overview of EGFR-Addicted NSCLC
Giuseppe Banna, Head of Translational Research and Clinical Trials Unit, Thoracic Tumours at Candiolo Cancer Institute IRCCS, shared on LinkedIn about a recent paper by Maxime Borgeaud et al. published in ACS Journals:
“Just published in CA: A Cancer Journal for Clinicians
Personalized care for patients with EGFR-mutant non-small cell lung cancer:
Navigating early to advanced disease management.
The discovery of activating EGFR mutations has revolutionized lung cancer management, paving the way for targeted tyrosine kinase inhibitors (TKIs) and ushering in an era of personalized care.
This must-read review provides a comprehensive and updated overview of EGFR-addicted NSCLC, from biology and early-stage treatment to advanced disease and resistance mechanisms.
Whatever you want to know about EGFR-mutant lung cancer, you’ll find it here.
It’s been a true privilege to contribute to this collaborative effort with such an outstanding team.”
Title: Personalized care for patients with EGFR-mutant nonsmall cell lung cancer: Navigating early to advanced disease management
Authors: Maxime Borgeaud, Timothée Olivier, Jair Bar, Stephanie Pei Li Saw, Kaushal Parikh, Giuseppe Luigi Banna, Claudio De Vito, Jill Feldman, Xiuning Le, Alfredo Addeo
More about Lung Cancer.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023